IPO mania fizzles in Hong Kong

Bloomberg

The days of the massive first-day pop in Hong Kong’s initial public offering (IPO)M frenzy may be nearing an end.
Even as the pandemic spread for most of 2020, the offshore Chinese city’s IPOs and new listings were in hot demand from both institutional and mom-and-pop investors. With the bulk of new share sales posting large gains on their first-day of trading, investor euphoria was justified.
Last year’s largely winning investor play of piling into IPOs and exiting after they debuted is no longer a slam dunk: 31% of thirteen IPOs raising more than $100 million posted losses on day one this year, almost double the 17% in 2020. A median first-day move showed gains of 2.1% in 2021 from 5.7% last year, reports said.
according to data compiled by Bloomberg.
“Most IPOs performed really, really strongly last year, but I’m not expecting that kind of movement this year,” said Joohee An, a fund manager at Mirae Asset Global Invest (HK) Ltd. Investors will be “more prudent” as market liquidity “won’t be as abundant as it used to be”, she added.
To be clear, listings by Kuaishou Technology and New Horizon Health Ltd. still did unusually well in February, with shares more than doubling on the first day.
But lukewarm post-listing performances are increasing. Chinese household insecticide company Cheerwin Group Ltd. slumped as much as 20% on its first trading day last week. Biopharmaceutical company SciClone Pharmaceuticals Holdings Ltd. ended its March 3 debut flat and is now trading 8.6% below its offer price.
The secondary listing wave of U.S.-listed Chinese companies hasn’t always had glowing debuts in Hong Kong. Autohome Inc., a Chinese online car-sales website with its primary listing in New York, ended its Hong Kong debut on Monday with a modest 2% rise.
Volatility sparked by the great rotation into previously unloved stocks sensitive to economic fluctuations from loftily valued tech and health-care plays is to blame, according to investors. Others also pointed to worries about policy being tightened in China as weighing on investors’ risk appetite for new stock, especially share sales by less well-known names.